Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASCO
Filter by Topic
ASCO 2014 Highlights
ASCO 2014 – Colorectal and Head & Neck Cancer
ASCO 2014 – Immuno-Oncology
ASCO 2014 – Lung Cancer
ASCO 2015 - Lung Cancer
ASCO 2015 Highlights
ASCO 2016 – Lung Cancer
ASCO 2017 – Multiple Myeloma
ASCO 2018 Insights
ASCO 2019
ASCO 2020 Cholangiocarcinoma
ASCO Breast Cancer Symposium
ASCO Quality Care Symposium
ASCO’s 1st Quality Care Symposium
Current Cost of Cancer Drugs Does Not Reflect Value, One Oncologist Suggests
By
Dana Taylor
ASCO 2015 Highlights
,
ASCO
July 2015, Vol 6, No 6
Chicago, IL—According to Leonard B. Saltz, MD, Chief of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center, NY, the cost of new cancer drugs is no longer sustainable. Dr Saltz presented “Perspectives on Value” at the Plenary Session of the 2015 American Society of Clinical Oncology meeting.
Read Article
Elotuzumab, First-in-Class Monoclonal Antibody Immunotherapy, Improves Outcomes in Patients with Multiple Myeloma
By
Phoebe Starr
ASCO 2015 Highlights
,
ASCO
June 2015, Vol 6, No 5
Elotzumab’s “double whammy” mechanism of action acts directly on the tumor itself and enhances the activity of natural killer cells to kill the tumor.
Read Article
Combination Immunotherapy Superior to Monotherapy in Patients with Melanoma
By
Chase Doyle
ASCO 2015 Highlights
,
ASCO
June 2015, Vol 6, No 5
Combination treatment with nivolumab and ipilimumab doubled progression-free survival in patients with advanced melanoma, according to CheckMate 067 investigators.
Read Article
Docetaxel Boosts Survival in Patients with Hormone-Naïve Metastatic Prostate Cancer
By
Phoebe Starr
ASCO 2015 Highlights
,
ASCO
June 2015, Vol 6, No 5
Chicago, IL—Adding docetaxel (Taxotere) to standard hormone therapy extends overall survival (OS) by a median of 10 months versus hormone therapy alone in men with newly diagnosed, advanced, hormone therapy–naïve prostate cancer, according to the results of the STAMPEDE trial. The survival benefits were more pronounced in metastatic disease and were less certain in nonmetastatic disease. Another finding of this analysis of STAMPEDE is that zoledronic acid (Zometa) had no benefit in this setting.
Read Article
Immunotherapy Makes Headwinds into Liver Cancer
By
Wayne Kuznar
ASCO 2015 Highlights
,
Immunotherapy
,
ASCO
June 2015, Vol 6, No 5
Chicago, IL—Immunotherapy with nivolumab (Opdivo) resulted in durable responses and promising overall survival (OS) in a dose-escalation and expansion trial of patients with advanced liver cancer. The 12-month OS rate exceeded 60% in patients in whom sorafenib (Nexavar) had failed, and responses occurred in patients with the hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, reported Anthony B. El-Khoueiry, MD, Assistant Professor of Clinical Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, at the 2015 American Society of Clinical Oncology (ASCO) meeting.
Read Article
Oral Nicotinamide Prevents Common Skin Cancers in High-Risk Patients
By
Phoebe Starr
ASCO 2015 Highlights
,
ASCO
June 2015, Vol 6, No 5
Chicago, IL—The prevention of common skin cancers and precancers is possible by taking an inexpensive, widely available, oral pill twice daily. The pill—the vitamin B3 supplement called nicotinamide—cut the rate of new squamous-cell and basal-cell skin cancers by 23% compared with placebo after 1 year among patients at high risk for skin cancer. Nicotinamide also reduced the risk for developing actinic keratosis, a common precancer of the skin.
Read Article
Encouraging Results for Pembrolizumab in Head and Neck Cancer
By
Phoebe Starr
ASCO 2015 Highlights
,
ASCO
June 2015, Vol 6, No 5
Chicago, IL—Pembrolizumab (Keytruda) achieved “remarkable” results in a phase 1 study of previously treated patients with recurrent, squamous-cell carcinoma of the head and neck, according to presenters at the 2015 American Society of Clinical Oncology (ASCO) annual meeting.
Read Article
Adding Radiation to First-Line FOLFOX Reduces Liver Metastases Progression in Patients with Metastatic Colorectal Cancer
By
Walter Alexander
ASCO 2015 Highlights
,
ASCO
June 2015, Vol 6, No 5
Chicago, IL—In patients with metastatic colorectal cancer (mCRC) with liver-dominant metastases who received first-line FOLFOX (leucovorin, fluorouracil [Adrucil], and oxaliplatin [Eloxatin]) with or without bevacizumab (Avastin) plus selective internal radiation therapy (SIRT) compared with FOLFOX with or without bevacizumab, progression-free survival (PFS) in the liver was extended by 7.9 months, according to the results of the SIRFLOX trial, which were presented at the 2015 American Society of Clinical Oncology (ASCO) meeting.
Read Article
Efficacy and Safety of BCD-021, a Bevacizumab Biosimilar Candidate, Compared to Avastin® in Patients with Advanced Nonsquamous NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
,
Biosimilars
Conference Correspondent
Read Article
Final Follow-up Results from RADIANT: Adjuvant Erlotinib Vs Placebo Following Complete Tumor Resection in Patients with Stage IB–IIIA EGFR-positive NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
Read Article
Page 6 of 19
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma